Provided by Tiger Fintech (Singapore) Pte. Ltd.

Co-diagnostics Inc.

0.3500
+0.00050.14%
Post-market: 0.35000.00000.00%17:09 EDT
Volume:76.88K
Turnover:27.26K
Market Cap:11.75M
PE:-0.28
High:0.3600
Open:0.3500
Low:0.3400
Close:0.3495
Loading ...

Company Profile

Company Name:
Co-diagnostics Inc.
Exchange:
NASDAQ
Establishment Date:
2013
Employees:
132
Office Location:
2401 S. Foothill Dr.,Suite D,Salt Lake City,Utah,United States
Zip Code:
84109
Fax:
- -
Introduction:
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Directors

Name
Position
Dwight H. Egan
Chief Executive Officer, President and Chairman of the Board
Edward L. Murphy
Director
Eugene Durenard
Director
James Nelson
Director
Richard S. Serbin
Director

Shareholders

Name
Position
Dwight H. Egan
Chief Executive Officer, President and Chairman of the Board
Brian Brown
Chief Financial Officer and Secretary